drugset / Trial / NCT01660750
A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma
NaSingle-groupOpen-labelTreatment
Summary
This is a dose finding pilot study to evaluate the safety and determine the maximum tolerated dose of the combination of carfilzomib and cyclophosphamide with dexamethasone (Car-Cy-Dex) prior to autologous stem cell transplant (ASCT) in patients with newly diagnosed transplant eligible multiple myeloma.
Timeline
- Start
- 2013-01
- Primary completion
- 2015-08
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carfilzomib | Other / unclassified | — | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | — | Oral |
| Subject | Dexamethasone | Small molecule | 40 mg | Oral |